Top Markets
Coin of the day
IMV Inc. IMV Inc.

IMV Inc.

IMV
株式のランク #35289
IMV Inc. is a clinical-stage biotechnology company dedicated to the development... IMV Inc. is a clinical-stage biotechnology company dedicated to the development of innovative immunotherapies. The company utilizes its proprietary DPX immune-educating technology platform to create a portfolio of treatments for various solid and hematological cancers. Its leading investigational drug, maveropepimut-S, is a DPX-based immunotherapy designed to target cancer cells that express survivin. Maveropepimut-S is currently undergoing Phase II clinical trials for diffuse large B-cell lymphoma, ovarian cancer, and specific bladder, liver, and microsatellite instability-high tumors, with Phase I trials also active for breast cancer. Beyond its primary candidate, IMV is also advancing DPX-SurMAGE, which is in Phase I clinical trials for bladder cancer, and is developing DPX-COVID-19 and DPX-RSV to address infectious diseases. Originally founded in 2000 as Immunovaccine Inc., the company adopted the name IMV Inc. in May 2018 and operates from its headquarters in Dartmouth, Canada.
株価
$0.82959892
最終同期: 2023-05-23
時価総額
$4.16M
変化(1日)
-0.04%
変化(1年)
0.00%
CA
取引 IMV Inc. (IMV)

カテゴリー

IMV Inc.(IMV)の株価履歴
終値の最高値: $0.83 (2023-05-01)

終値の最安値: $10.12 (2012-08-01)
IMV Inc. の株価履歴(2012 ~ 2026)
年間株価パフォーマンス
パフォーマンス
2023 -68.78%
2022 -80.40%
2021 -58.02%
2020 14.41%
2019 -48.63%
2018 2.19%
2017 210.21%
2016 -3.76%
2015 -10.27%
2014 42.27%
2013 23.64%
2012 0.00%
類似企業または競合の株価
企業 株価 変化率 1年%
$505.24 28.63%
US
$846.09 29.41%
NL
$731.69 6.47%
CH
$1.07K -6.40%
KR
$251.82 11.75%
BE